Relationship between bullous pemphigoid and immunization against COVID-19
Keywords:
SARS-CoV-2, COVID-19, bullous pemphigoid, immunizationAbstract
Introduction: through the application of the vaccine against SARS-CoV-2, some cases of bullous pemphigoid have been reported, with adults and older adults being affected. The clinical manifestations developed a few days after the first or second dose against COVID-19 was administered. Objective: to describe the possible relationship between the development of bullous pemphigoid after immunization against the COVID-19 virus. Method: a bibliographic review was carried out where original articles and systematic reviews from the last 3 years were analyzed that provide information on the relationship between the development of bullous pemphigoid and immunization against COVID-19. The search was carried out through databases such as PubMed, SciELO and ClinicalKey, in addition, keywords such as: bullous pemphigoid, COVID-19 or SARS-CoV-2, SARS-CoV-2 vaccine, were used in the Google Scholar search engine. immunosuppression. Results: the studies and articles analyzed presented cases of patients who developed bullous pemphigoid after receiving the first or second dose against the SARS-CoV-2 virus. It affects the adult population between 53 and 80 years old. The cases show that it occurs in both men and women, but with a higher risk of appearance and exacerbations in patients over 75 years of age. In recent years, its incidence has increased slightly as a result of immunization against COVID-19. Conclusion: the exhaustive review of various published articles and studies has shown a relationship between immunization and the development of bullous pemphigus, its research should not be left aside, especially in terms of its pathophysiology in order to improve treatment.
Downloads
References
2. Vila M. Vacunas COVID-19: clasificación, características y objetivo [Interner]. Quirón prevención; 2021. Disponible en: https://www.quironprevencion.com/blogs/es/prevenidos/vacunas-covid-19-clasificacion-caracteristicas-objetivo
3. Pérez-Corrales LL, Flores-Madrigal NE, Valencia-Álvarez M, Serrano-González A, López-Martínez DA. Penfigoide ampolloso asociado con vacuna contra COVID-19. Dermatol Rev Mex. 2021; 65 (6):1014-1016.
4. Maronese CA, Caproni M, Moltrasio C, Genovese G, Vezzoli P, Sena P, Previtali G, et al. () Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study. Front Med. 2022; 9:841506. DOI: 10.3389/fmed.2022.841506
5. Aashish, Rai A, Khatri G, Priya, Hasan MM. Bullous pemphigoid following COVID-19 vaccine: An autoimmune disorder. Ann Med Surg (Lond). 2022 Aug; 80:104266. DOI: 10.1016/j.amsu.2022.104266
6. Martínez-Villarreal JD, Cuéllar-Barboza A, Cárdenas-de la Garza JA, Flores-Pérez RO. Perlas de medicina interna en enfermedades ampollosas autoinmunitarias. Dermatol Rev Mex. 2019 mayo-jun.; 63(3):293-301.
7. Alshammari F, Abuzied Y, Korairi A, Alajlan M, Alzomia M, AlSheef M. Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report. Ann Med Surg (Lond). 2022 Mar; 75:103420. DOI: 10.1016/j.amsu.2022.103420
8. Tan SW, Tam YC, Pang SM. Cutaneous reactions to COVID-19 vaccines: A review (Reaccionescutáneas a las vacunas COVID-19: revisión). J Am Acad Dermatol. 2022: 178-186. DOI: 10.1016/j.jdin.2022.01.011
9. Macías-Macías AI, Saavedra-Casas OG, Capilla-García MH, Hernández-Collazo AA. Recaída de penfigoide ampolloso posterior a la aplicación de la vacuna de virus atenuados contra COVID-19. Dermatol Rev Mex. 2021; 65(6):1017-1020.
10. Pérez-Corrales LL, Flores-Madrigal NE, Valencia-Álvarez M, Serrano-González A, López-Martínez DA. Penfigoide ampolloso asociado con vacuna contra COVID-19. Dermatol Rev Mex. 2021; 65(6):1014-1016.
11. Montornès- Montmeló E, Hovhannisyan A. Pénfigo ampolloso en una paciente encamada. Camfic Cat [Internet]. [citado 13 Mar 2023]. Disponible en: http://gestorweb.camfic.cat/uploads/ITEM_6848_ART_485.pdf
12. Cabanillas-Becerra JJ, Guerra-Arias C. Bullous pemphigoid. Dermatol [Internet]. 2004 [citado Mar 2023], 21(2). Disponible en: https://sisbib.unmsm.edu.pe/bvrevistas/dermatologia/v21_n2/pdf/a04v21n2.pdf
13. Tirado A, Enfermedades ampollosas autoinmunitarias. Avances importantes. Dermatol Rev Mex [Internet]. 2019 sep-oct. [citado 25 Oct 2023]; 63(5):439-440. DOI: 10.1111/ijd. 13654
14. Forero E, Chalem M, Vásquez G, Jauregui E, Medina LF, Pinto Peñaranda LF, et al. Gestión de riesgo para la prescripción de terapias biológicas. Rev Colomb Reumatol [Internet]. 2016 [citado 25 Oct 2032]; 23(1):50-67. Disponible en: https://sad.org.ar/wp-content/uploads/2021/09/Guias-de-manejo-de-PA.pdf
15. Suárez-Carantoña C, Jiménez-Cauhé J, González-García A, Fernández-Guarino M, Asunción Ballester M. Baja dosis de rituximab para penfigoide ampolloso. Protocolo y experiencia de un único centro. Actas Dermosifiliogr [Internet]. 2023 [citado 13 Mar 2023]; 114(1):T62-8. Disponible en: https://www.actasdermo.org/es-articulo-traducido-baja-dosis-rituximab-articulo-S0001731022009346
